Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis

Abstract

These results suggest that lexipafant may be a useful adjunct to full supportive care in the early management of patients with severe acute pancreatitis.

Natural History of Organ Failure in Acute Pancreatitis

“…At that time it was believed reasonable to use the development of MODS as a study end point. Unfortunately, the two larger UK studies of lexipafant in acute pancreatitis both found that 70% of patients who developed MODS had evidence of this at admission to hospital [3,11]. Not only did this render much of the effort in carrying out these trials futile, it challenged the perception that patients with severe acute pancreatitis develop MODS over a 48-to 72-hour period after admission.…”

“…These figures are in keeping with results from prospective clinical trials reported from UK and European centres. In the UK multi-centre trial of lexipafant [3], 40% of deaths occurred within the first week, and early mortality in two single-centre studies from the west of Scotland was identical [10,11].…”

Clinical usefulness of serum carboxypeptidase B activation peptide in acute pancreatitis

“…Early identification of severely ill patients is helpful in order to insure both rapid and appropriate treatment; endoscopic sphincterotomy has become more widely applied for the management of severe gallstone-induced acute pancreatitis [1,2] and other specific therapies are available or being developed [3][4][5]. The earlier these treatments are applied, the more effective they will be in the prevention of complications.…”

Acute Pancreatitis: Treatment Strategies

“…This condition however is not very useful in clinical practice and is limited to the use of gabexate mesilate for prevention of ERP-induced acute pancreatitis. Lexipafant, a potent antagonist of platelet-activating factor (PAF), was a new promising candidate probably effective in experimentally induced pancreatitis in rats, as well as in an initial pilot study in humans showing reduced pancreatic and extrapancreatic inflammation as well as a reduction in organ complications [88]. However, in a recent large unpublished multicenter study, a beneficial effect was not confirmed [89].…”